Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Valganciclovir

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    47 result(s) found for: Valganciclovir. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2015-004406-42 Sponsor Protocol Number: FCO-TIM-2015-01 Start Date*: 2016-03-10
    Sponsor Name:FIBICO
    Full Title: CLINICAL TRIAL TO ASSEES THE NON-INFERIORITY OF THE SUSPENSION OF PROPHYLACTIC TREATMENT WITH VALGANCICLOVIR IN KIDNEY TRANSPLANT CMV-seropositive PATIENTS, WHO MANTEIN CD8+ CMV- CELLULAR IMMUNI...
    Medical condition: Kidney transplant cytomegalovirus-seropositive
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001083-30 Sponsor Protocol Number: VIGAS2 Start Date*: 2019-06-02
    Sponsor Name:Karolinska Institutet
    Full Title: A multicenter randomized double-blinded controlled phase 2 study evaluating the efficacy of valganciclovir as add-on therapy in glioblastoma patients
    Medical condition: Glioblastoma is an incurable brain tumor with very dismal prognosis. Substantial evidence demonstrates that cytomegalovirus (CMV) is present in 90-100% of malignant glioblastoma.We have observed th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-000231-29 Sponsor Protocol Number: WV16726 Start Date*: 2004-08-12
    Sponsor Name:Roche Products Ltd
    Full Title: Safety and pharmacokinetics of valganciclovir syrup formulation in paediatric solid organ transplant recipients
    Medical condition: solid organ transplants
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002817-19 Sponsor Protocol Number: NT18435 Start Date*: Information not available in EudraCT
    Sponsor Name:F Hoffmann-La Roche Ltd
    Full Title: A randomised, double blind, placebo controlled multicentre study of the efficacy and safety of up to 100 days of valganciclovir vs up to 200 days of valganciclovir for prevention of cytomegalovirus...
    Medical condition: Prevention of cytomegalovirus (CMV) disease in kidney transplant recipients
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) ES (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004726-34 Sponsor Protocol Number: SHP620-302 Start Date*: 2017-09-01
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegaloviru...
    Medical condition: Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021819 Infection in marrow transplant recipients LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) CZ (Completed) PL (Completed) FR (Completed) HR (Completed) IT (Completed) GR (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-024247-32 Sponsor Protocol Number: 1263-203 Start Date*: 2012-03-09
    Sponsor Name:VIROPHARMA INCORPORATED
    Full Title: A PHASE 2, RANDOMIZED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND ANTI-CYTOMEGALOVIRUS (CMV) ACTIVITY OF MARIBAVIR VERSUS VALGANCICLOVIR FOR TREATMENT OF CMV INFECTIONS IN TRANSPLANT RECIPIENTS WH...
    Medical condition: CMV INFECTIONS IN TRANSPLANT RECIPIENTS
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10021819 Infection in marrow transplant recipients LLT
    14.1 100000004862 10021829 Infection in solid organ transplant recipients LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) AT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002233-11 Sponsor Protocol Number: ELISPOT-TC Start Date*: 2020-01-16
    Sponsor Name:Dr. José González Costello.Unidad de Insuficiencia cardíaca avanzada y Trasplante cardíaco. Hospital Univ. Bellvitge
    Full Title: The proposed study is a phase IV, randomized, controlled, multicenter and open clinical trial, with two parallel groups, to evaluate the effectiveness of a preventive strategy against CMV infection...
    Medical condition: We will investigate the benefits of monitoring the CMV-specific cellular response using the ELISPOT INF-y technique in patients with a positive serology against CMV, allowing the individualization ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10058666 Cytomegalovirus infection reactivation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005508-14 Sponsor Protocol Number: 08/0171 Start Date*: 2010-02-09
    Sponsor Name:University College london
    Full Title: A phase 3 randomized, placebo-controlled blinded investigation of six weeks vs. six months of oral valgancoclovir therapy in infants with symtomatic congenital cytomegalovirus infection. DMID # 06-...
    Medical condition: Symptomatic Congenital Cytomegalovirus.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10010430 Congenital cytomegalovirus infection PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004695-20 Sponsor Protocol Number: ML19313 Start Date*: 2006-03-27
    Sponsor Name:Roche Pharma AG
    Full Title: Randomized multicenter trial comparing Valganciclovir CMV prophylaxis versus pre-emptive therapy after renal transplantation using proteomics for monitoring of graft alteration
    Medical condition: Prevention of cytomegalovirus (CMV) disease in kidney transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015965-29 Sponsor Protocol Number: ML 22371 Start Date*: 2010-05-17
    Sponsor Name:Pierrel Research Europe GmbH
    Full Title: Multicenter, randomized study comparing oral valganciclovir versus intravenous ganciclovir in patients following allogeneic stem cell transplantation
    Medical condition: Patients with a first episode of positive CMV-PCR (DNAemia) or pp65 antigenemia assay (antigenemia) up to 100 days after allogeneic SCT.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10011831 Cytomegalovirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004725-13 Sponsor Protocol Number: SHP620-303 Start Date*: Information not available in EudraCT
    Sponsor Name:Shire ViroPharma Incorporated
    Full Title: A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients...
    Medical condition: CMV infections resistant or refractory in transplant patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021819 Infection in marrow transplant recipients LLT
    20.0 100000004862 10021829 Infection in solid organ transplant recipients LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed) ES (Completed) FR (Completed) AT (Completed) HR (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001032-54 Sponsor Protocol Number: 19PH192 Start Date*: 2019-07-23
    Sponsor Name:CHU de Saint Etienne
    Full Title: Impact of anti-cytomegalovirus (valganciclovir) treatment in the management of relapsing ulcerative colitis (UC) requiring vedolizumab therapy: a randomized clinical trial comparing a strategy with...
    Medical condition: Patient with active ulcerative colitis who failed to anti-TNF with endoscopic active disease with an endoscopic Mayo score> 1 and 2 biopsies of the inflammatory tissue and presence of a CMV infect...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.1 100000004862 10058881 Cytomegalovirus viremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006980-35 Sponsor Protocol Number: PROTECT Start Date*: 2009-01-20
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Efficacy and safety of anti-cytomegalovirus prophylaxis versus pre-emptive approaches with valganciclovir in heart transplant recipients treated with everolimus or mycophenolate. A randomized open-...
    Medical condition: Heart transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019315 Heart transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021172-28 Sponsor Protocol Number: NP22523 Start Date*: 2010-10-28
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Farmacocinética y seguridad de valganciclovir en pacientes pediátricos < 4 meses de edad, receptores de trasplante cardíaco. Pharmacokinetics and safety of valganciclovir in pediatric heart transpl...
    Medical condition: Prevención de la enfermedad por CMV en receptores de trasplantes de órganos sólidos Prevention of CMV disease in solid organ transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009701 CMV LLT
    12.1 10049107 CMV viraemia LLT
    12.1 10060577 CMV viremia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004745-28 Sponsor Protocol Number: V.1.1 Start Date*: 2008-09-04
    Sponsor Name:Medizinische Universität Wien, KIM III, Abteilung für Nephrologie
    Full Title: Certican (Everolimus®) against Cytomegalovirus Disease in Renal Transplant Patients
    Medical condition:
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005197-10 Sponsor Protocol Number: VT3996-202 Start Date*: 2021-10-01
    Sponsor Name:Viracta Therapeutics, Inc.
    Full Title: An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
    Medical condition: Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071441 Epstein-Barr virus associated lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005378-44 Sponsor Protocol Number: CMV-MM-1 Start Date*: 2012-05-03
    Sponsor Name:LUMC
    Full Title: CONgenital Cmv: Efficacy of antiviral treatment in a Randomized controlled Trial
    Medical condition: Congenital cytomegalovirus infection. Sensorineural Hearingloss.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10010420 Congenital CMV infection LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003068-30 Sponsor Protocol Number: CMV-MM-2 Start Date*: 2013-09-30
    Sponsor Name:LUMC
    Full Title: CONgenital Cytomegalovirus: Efficacy of antiviral treatment in a non-Randomized Trial with historical control group
    Medical condition: Congenital cytomegalovirus infection. Sensorineural Hearingloss.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10010420 Congenital CMV infection LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-022514-47 Sponsor Protocol Number: NV25409 Start Date*: 2011-09-05
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients
    Medical condition: Treatment and prevention of CMV disease in kidney transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004862 10049107 CMV viraemia LLT
    16.0 100000004862 10009703 CMV infection LLT
    16.0 100000004848 10009701 CMV LLT
    16.0 100000004862 10060577 CMV viremia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) FR (Ongoing) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002912-15 Sponsor Protocol Number: CHUBX2016/40 Start Date*: 2017-10-03
    Sponsor Name:CHU de Bordeaux
    Full Title: Secondary Prophylaxis after CMV disease in Kidney transplant patients targeted by γδ T cells immunomonitoring.
    Medical condition: Kidney transplants patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 12:07:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA